Temozolomide-associated Blepharoconjunctivitis

Abstract

Abstract Background: Temozolomide (TMZ) is an effective oral alkylating agent used in treating various malignancies. It works by introducing methyl groups into DNA, inhibiting cell division. While highly effective in treating glioblastoma multiforme (GBM) and high-grade gliomas, TMZ use is associated with increased adverse event risks. Case Presentation: We present a case of a 58-year-old African-American man diagnosed with GBM. Following adjuvant TMZ treatment, he developed blepharoconjunctivitis, characterized by eyelid and conjunctival inflammation. Symptoms included eyelid swelling, crusting, and conjunctival discharge, which were promptly resolved with topical steroid cream and eye drops. Conclusions: Reports specifically linking TMZ to blepharoconjunctivitis are limited. The exact mechanism remains unclear but may involve inflammation extending from blepharitis to the conjunctiva. Healthcare providers must recognize and manage ophthalmic complications promptly. This case report highlights blepharoconjunctivitis associated with TMZ use in a GBM patient. While TMZ is an effective treatment, ophthalmic side effects can occur.